Skip to main content
Erschienen in: Wiener klinische Wochenschrift 11-12/2012

01.06.2012 | original article

Strength of skeletal muscle and self-reported physical performance in Austrian glioblastoma-patients

verfasst von: Mohammad Keilani, MD, MSc, Christoph Krall, PhD, Christine Marosi, MD, Birgit Flechl, MD, Karin Dieckmann, MD, Georg Widhalm, MD, Maximilian Marhold, Richard Crevenna, MBA, MSc

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 11-12/2012

Einloggen, um Zugang zu erhalten

Summary

Background

Aim of this study was to describe longitudinal assessments of handgrip strength, strength of thigh muscles, and self-reported physical performance in patients with glioblastoma after neurosurgical intervention undergoing chemoradiation.

Methods

Strength testing was performed in 24 Austrian glioblastoma patients (m:f = 19:5, 52 ± 14a, BMI = 26 ± 3 kg/m²) at baseline and follow up after chemoradiation (interval between baseline and follow up = 14 ± 9 weeks). Isokinetic testing of knee extension/flexion was performed by using a Biodex 3 dynamometer. Handgrip strength was measured by using a Jamar hand-dynamometer. Physical performance was assessed by using the subscales “physical functioning” and “role physical” of the SF-36 Health Survey.

Results

Peak torque of knee extensors (peak torque) were clearly lower than expected for age- and sex-related values (p < 0.0001). In comparison with age- and sex-related reference values, deficits of “role physical” (p < 0.0001) and “physical functioning” (p = 0.010) were found.
Effects of measurements of muscle strength on “physical functioning” were significant (peak torque:p < 0.001; handgrip strength:p < 0.001).
No significant change could be detected after follow up for peak torque (p = 0.337), handgrip strength (p = 0.995), “physical functioning” (p = 0.824), and “role physical” (0.594).

Conclusions

In this study, notable deficits especially in muscular strength of thigh muscles and general physical performance of patients with glioblastoma have been found before and after chemoradiation. Reduced muscle strength and impaired self-reported physical performance seem to be clinically relevant functional deficits in (Austrian) glioblastoma patients. Therefore, rehabilitation and supportive care should also include options to increase muscle strength.
Literatur
1.
Zurück zum Zitat Jones LW, Friedman AH, West MJ, et al. Quantitative assessment of cardiorespiratory fitness, skeletal muscle function, and body composition in adults with primary malignant glioma. Cancer. 2010;116:695–704.PubMedCrossRef Jones LW, Friedman AH, West MJ, et al. Quantitative assessment of cardiorespiratory fitness, skeletal muscle function, and body composition in adults with primary malignant glioma. Cancer. 2010;116:695–704.PubMedCrossRef
2.
Zurück zum Zitat Jones LW, Mourtzakis M, Peters KB, et al. Changes in functional performance measures in adults undergoing chemoradiation for primary malignant glioma: a feasibility study. Oncologist. 2010;15:636–47.PubMedCrossRef Jones LW, Mourtzakis M, Peters KB, et al. Changes in functional performance measures in adults undergoing chemoradiation for primary malignant glioma: a feasibility study. Oncologist. 2010;15:636–47.PubMedCrossRef
3.
Zurück zum Zitat Jones LW, Cohen RR, Mabe SK, et al. Assessment of physical functioning in recurrent glioma: preliminary comparison of performance status to functional capacity testing. J Neurooncol. 2009;94:79–85.PubMedCrossRef Jones LW, Cohen RR, Mabe SK, et al. Assessment of physical functioning in recurrent glioma: preliminary comparison of performance status to functional capacity testing. J Neurooncol. 2009;94:79–85.PubMedCrossRef
4.
Zurück zum Zitat Sturdza A, Millar BA, Bana N, et al. The use and toxicity of steroids in the management of patients with brain metastases. Support Care Cancer. 2008;16:1041–8.PubMedCrossRef Sturdza A, Millar BA, Bana N, et al. The use and toxicity of steroids in the management of patients with brain metastases. Support Care Cancer. 2008;16:1041–8.PubMedCrossRef
6.
Zurück zum Zitat Batchelor TT, Taylor LP, Thaler HT, Posner JB, DeAngelis LM. Steroid myopathy in cancer patients. Neurology. 1997;48:1234–8.PubMedCrossRef Batchelor TT, Taylor LP, Thaler HT, Posner JB, DeAngelis LM. Steroid myopathy in cancer patients. Neurology. 1997;48:1234–8.PubMedCrossRef
7.
8.
Zurück zum Zitat Dropcho EJ, Soong SJ. Steroid-induced weakness in patients with primary brain tumors. Neurology. 1991;41:1235–9.PubMedCrossRef Dropcho EJ, Soong SJ. Steroid-induced weakness in patients with primary brain tumors. Neurology. 1991;41:1235–9.PubMedCrossRef
9.
Zurück zum Zitat Mitra R. Adverse effects of corticosteroids on bone metabolism: a review. PM&R. 2011;3:466–71.CrossRef Mitra R. Adverse effects of corticosteroids on bone metabolism: a review. PM&R. 2011;3:466–71.CrossRef
10.
Zurück zum Zitat Maruotti N, Corrado A, Cantatore FP. Glucocorticoid induced risk of fractures. Panminerva Med. 2010;52:339–43.PubMed Maruotti N, Corrado A, Cantatore FP. Glucocorticoid induced risk of fractures. Panminerva Med. 2010;52:339–43.PubMed
11.
Zurück zum Zitat Cohen SB. Comorbidities: glucocorticoids and osteoporosis: predicting fracture risk. Nat Rev Rheumatol. 2010;6:681–2.PubMedCrossRef Cohen SB. Comorbidities: glucocorticoids and osteoporosis: predicting fracture risk. Nat Rev Rheumatol. 2010;6:681–2.PubMedCrossRef
12.
Zurück zum Zitat Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet. 1997;349:1050–3.PubMedCrossRef Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet. 1997;349:1050–3.PubMedCrossRef
13.
Zurück zum Zitat Hülsmann M, Quittan M, Berger R, et al. Muscle strength as a predictor of long-term survival in severe congestive heart failure. Eur J Heart Fail. 2004;6:101–7.PubMedCrossRef Hülsmann M, Quittan M, Berger R, et al. Muscle strength as a predictor of long-term survival in severe congestive heart failure. Eur J Heart Fail. 2004;6:101–7.PubMedCrossRef
14.
Zurück zum Zitat Drouin JM, Valovich-mcLeod TC, Shultz SJ, Gansneder BM, Perrin DH. Reliability and validity of the Biodex system 3 pro isokinetic dynamometer velocity, torque, and position measurements. Eur J Appl Physiol. 2004;91:22–9.PubMedCrossRef Drouin JM, Valovich-mcLeod TC, Shultz SJ, Gansneder BM, Perrin DH. Reliability and validity of the Biodex system 3 pro isokinetic dynamometer velocity, torque, and position measurements. Eur J Appl Physiol. 2004;91:22–9.PubMedCrossRef
15.
Zurück zum Zitat Crevenna R, Mähr B, Fialka-Moser V, Keilani M. Strength of skeletal muscle and quality of life in patients suffering from “typical male” carcinomas. Support Care Cancer. 2009;17:1225–8.CrossRef Crevenna R, Mähr B, Fialka-Moser V, Keilani M. Strength of skeletal muscle and quality of life in patients suffering from “typical male” carcinomas. Support Care Cancer. 2009;17:1225–8.CrossRef
16.
Zurück zum Zitat Feiereisen P, Vaillant M, Eischen D, Delagardelle C. Isokinetic versus one-repetition maximum strength assessment in chronic heart failure. Med Sci Sports Exerc. 2010;42:2156–63.PubMedCrossRef Feiereisen P, Vaillant M, Eischen D, Delagardelle C. Isokinetic versus one-repetition maximum strength assessment in chronic heart failure. Med Sci Sports Exerc. 2010;42:2156–63.PubMedCrossRef
17.
Zurück zum Zitat Quittan M, Wiesinger GF, Crevenna R, et al. Isokinetic strength testing in patients with chronic heart failure—a reliability study. Int J Sports Med. 2001;22:40–4.PubMedCrossRef Quittan M, Wiesinger GF, Crevenna R, et al. Isokinetic strength testing in patients with chronic heart failure—a reliability study. Int J Sports Med. 2001;22:40–4.PubMedCrossRef
18.
Zurück zum Zitat Biodex Multi joint System 3 PRO. Application/operations manual. Biodex Medical Systems Shirley. New York; 2000. Biodex Multi joint System 3 PRO. Application/operations manual. Biodex Medical Systems Shirley. New York; 2000.
19.
Zurück zum Zitat Harbo T, Brincks J, Andersen H. Maximal isokinetic and isometric muscle strength of major muscle groups related to age, body mass, height, and sex in 178 healthy subjects. Eur J Appl Physiol. 2001 May 3. Epub ahead of print. Harbo T, Brincks J, Andersen H. Maximal isokinetic and isometric muscle strength of major muscle groups related to age, body mass, height, and sex in 178 healthy subjects. Eur J Appl Physiol. 2001 May 3. Epub ahead of print.
20.
Zurück zum Zitat Perrin DH. Isokinetic exercise and assessment. Champaign: Human Kinetics; 1993. Perrin DH. Isokinetic exercise and assessment. Champaign: Human Kinetics; 1993.
21.
Zurück zum Zitat Harkonen Harju R, Alaranta H. Accuracy of the Jamar dynamometer. J Hand Ther. 1993;6:259–62.CrossRef Harkonen Harju R, Alaranta H. Accuracy of the Jamar dynamometer. J Hand Ther. 1993;6:259–62.CrossRef
22.
Zurück zum Zitat Peters MJ, van Nes SI, Vanhoutte EK, on behalf of the PeriNomS Study group, et al. Revised normative values for grip strength with Jamar Dynamometer. J Peripher Nerv Syst. 2011;16:47–50.PubMedCrossRef Peters MJ, van Nes SI, Vanhoutte EK, on behalf of the PeriNomS Study group, et al. Revised normative values for grip strength with Jamar Dynamometer. J Peripher Nerv Syst. 2011;16:47–50.PubMedCrossRef
23.
Zurück zum Zitat American Society of Hand Therapists. Clinical Assessment Recommendations. 2nd edn. Chicago: The Society; 1992. p. 41–5. American Society of Hand Therapists. Clinical Assessment Recommendations. 2nd edn. Chicago: The Society; 1992. p. 41–5.
24.
Zurück zum Zitat Mathiowetz V. Grip and pinch strength measurements. In: Amundsen LR, editor. Muscle strength testing instrumented and noninstrumented systems. New York: Churchill Livingstone; 1990. p. 163–77. Mathiowetz V. Grip and pinch strength measurements. In: Amundsen LR, editor. Muscle strength testing instrumented and noninstrumented systems. New York: Churchill Livingstone; 1990. p. 163–77.
25.
Zurück zum Zitat Bullinger M. German translation and psychometric testing of the SF-36 Health Survey: preliminary results from the IQOLA Project. International Quality of Life Assessment. Soc Sci Med. 1995;41:1359–66.PubMedCrossRef Bullinger M. German translation and psychometric testing of the SF-36 Health Survey: preliminary results from the IQOLA Project. International Quality of Life Assessment. Soc Sci Med. 1995;41:1359–66.PubMedCrossRef
26.
27.
Zurück zum Zitat Gorlia T, Van Den Bent MJ, Hegi ME, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol. 2008;9:29–38.PubMedCrossRef Gorlia T, Van Den Bent MJ, Hegi ME, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol. 2008;9:29–38.PubMedCrossRef
28.
Zurück zum Zitat Stupp R, Hegi ME, Mason WP, European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups, National Cancer Institute of Canada Clinical Trials Group, et al. Effects of radiotherapy with concomitant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–66.PubMedCrossRef Stupp R, Hegi ME, Mason WP, European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups, National Cancer Institute of Canada Clinical Trials Group, et al. Effects of radiotherapy with concomitant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–66.PubMedCrossRef
29.
Zurück zum Zitat Weiler M, Hartmann C, Wiewrodt D, et al. Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide. Int J Radiat Oncol Biol Phys. 2010;77:670–6.PubMedCrossRef Weiler M, Hartmann C, Wiewrodt D, et al. Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide. Int J Radiat Oncol Biol Phys. 2010;77:670–6.PubMedCrossRef
30.
31.
Zurück zum Zitat Kvale EA, Murthy R, Taylor R, Lee JY, Nabors LB. Distress and quality of life in primary high-grade brain tumor patients. Support Care Cancer. 2009;17:793–9.PubMedCrossRef Kvale EA, Murthy R, Taylor R, Lee JY, Nabors LB. Distress and quality of life in primary high-grade brain tumor patients. Support Care Cancer. 2009;17:793–9.PubMedCrossRef
32.
Zurück zum Zitat Lamperti E, Pantaleo G, Finocchiaro CY, et al. Recurrent brain tumour: the impact of illness on patient’s life. Support Care Cancer. 2011 Jul 3. Epub ahead of print. Lamperti E, Pantaleo G, Finocchiaro CY, et al. Recurrent brain tumour: the impact of illness on patient’s life. Support Care Cancer. 2011 Jul 3. Epub ahead of print.
33.
Zurück zum Zitat Wijndaele K, Duvigneaud N, Matton L, et al. Muscular strength, aerobic fitness, and metabolic syndrome risk in Flemish adults. Med Sci Sports Exerc. 2007;39:233–40.PubMedCrossRef Wijndaele K, Duvigneaud N, Matton L, et al. Muscular strength, aerobic fitness, and metabolic syndrome risk in Flemish adults. Med Sci Sports Exerc. 2007;39:233–40.PubMedCrossRef
Metadaten
Titel
Strength of skeletal muscle and self-reported physical performance in Austrian glioblastoma-patients
verfasst von
Mohammad Keilani, MD, MSc
Christoph Krall, PhD
Christine Marosi, MD
Birgit Flechl, MD
Karin Dieckmann, MD
Georg Widhalm, MD
Maximilian Marhold
Richard Crevenna, MBA, MSc
Publikationsdatum
01.06.2012
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 11-12/2012
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-012-0186-1

Weitere Artikel der Ausgabe 11-12/2012

Wiener klinische Wochenschrift 11-12/2012 Zur Ausgabe